Business Description
Artelo Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US04301G6070
Total Employee Number:
7Description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 14.29 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 17 | |||||
3-Year EPS without NRI Growth Rate | 19.5 | |||||
3-Year FCF Growth Rate | 21.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.09 | |||||
9-Day RSI | 27.69 | |||||
14-Day RSI | 30 | |||||
3-1 Month Momentum % | -79.4 | |||||
6-1 Month Momentum % | -61.94 | |||||
12-1 Month Momentum % | -95.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.79 | |||||
Quick Ratio | 1.79 | |||||
Cash Ratio | 1.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -61.8 | |||||
Shareholder Yield % | -436.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -1677.67 | |||||
ROA % | -245.19 | |||||
ROIC % | -394.54 | |||||
3-Year ROIIC % | -182.22 | |||||
ROC (Joel Greenblatt) % | -17895.89 | |||||
ROCE % | -1551.54 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.15 | |||||
Price-to-Tangible-Book | 0.21 | |||||
EV-to-EBIT | 0.44 | |||||
EV-to-EBITDA | 0.44 | |||||
EV-to-FCF | 0.7 | |||||
| Price-to-Net-Current-Asset-Value | 0.21 | |||||
| Price-to-Net-Cash | 0.22 | |||||
Earnings Yield (Greenblatt) % | 227.27 | |||||
FCF Yield % | -209.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARTL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Artelo Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -38.93 | ||
| Beta | -0.9991 | ||
| 3-Year Sharpe Ratio | -0.34 | ||
| 3-Year Sortino Ratio | -0.56 | ||
| Volatility % | 167.42 | ||
| 14-Day RSI | 30 | ||
| 14-Day ATR ($) | 0.151173 | ||
| 20-Day SMA ($) | 1.2465 | ||
| 12-1 Month Momentum % | -95.62 | ||
| 52-Week Range ($) | 1.03 - 85.8 | ||
| Shares Outstanding (Mil) | 3.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Artelo Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Artelo Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 40 days | ||
| General meeting for 2026 | 2026-07-17 08:00 | In 14 days | ||
| First quarter earnings results for 2026 | 2026-05-13 | 2.40 (-2.44%) | ||
| 0.333333:1 Stock Split | 2026-03-10 | 3.51 (-4.88%) | ||
| Annual report for 2025 | 2026-02-24 | 3.72 (-4.62%) | ||
| General meeting for 2025 | 2026-01-30 08:00 | 5.04 (-6.67%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 5.88 (+1.55%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 29.16 (-4.33%) | ||
| 0.166667:1 Stock Split | 2025-06-13 | 21.25 (-0.77%) |
Show
Entries
Artelo Biosciences Inc Frequently Asked Questions
What is Artelo Biosciences Inc(ARTL)'s stock price today?
The current price of ARTL is $1.11. The 52 week high of ARTL is $85.80 and 52 week low is $1.03.
When is next earnings date of Artelo Biosciences Inc(ARTL)?
The next earnings date of Artelo Biosciences Inc(ARTL) is 2026-08-13 Est..
Does Artelo Biosciences Inc(ARTL) pay dividends? If so, how much?
Artelo Biosciences Inc(ARTL) does not pay dividend.
Guru Commentaries on NAS:ARTL
No articles.
Press Release
Articles on Artelo Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers